secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2026-08-13T20:07:52+00:00
Accession:  0001125345-26-000054
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics Q2 net income $19.5M; sells manufacturing to Bora for $122.5M, cash runway to 2028
--------------------------------------------------------------------------------

- Q2 2026 revenue $32.8M vs $6.9M YoY; net income $19.5M vs net loss $36.3M YoY, driven by $24.5M Sanofi TZIELD milestone and $89.2M discontinued ops gain.
- Completed sale of GMP manufacturing to Bora for $122.5M base price; received $119.6M cash at closing; workforce cut to ~140 employees.
- Pro forma cash $327M as of June 30, 2026 (incl. Bora, Sanofi, Gilead proceeds); cash runway guided through 2028.
- Gilead exercised option for preclinical bispecific program, triggering $10.0M payment; eligible for up to ~$2.4B in future milestones from partners.
- Pipeline: MGC026 SCCHN cohort met threshold to advance to Stage 2; MGC030 IND cleared, first patient Q3 2026; MGC028 update late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/0001125345-26-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/mgnx-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001125345-26-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer